17 completed, 7 terminated, 3 unknown, 2 withdrawn. 12 Not applicable, 9 Phase 2, 6 Phase 1, 2 Phase 3, 1 Phase 4.
Follow Hemoglobin SC Disease: new trials by email Literature Review of Hemoglobin SC Disease trials Research Report on Hemoglobin SC Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Buprenorphine for the Management of Pain in Children With Sickle Cell Disease Buprenorphine Buccal Film [Belbuca] - Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis | Phase 1 | Not yet recruiting | Natasha Archer | 25 | 2026-10-01 | 2026-09-02 |
| Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease Sickle Cell Anemia, Sickle Cell Thalassemia | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 6 | 2024-05-09 | 2026-09-22 | |
| An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients crizanlizumab - Sickle Cell Disease (SCD) | Phase 4 | Completed | Novartis Pharmaceuticals | 140 | 2021-07-14 | 2025-09-26 |
| The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD. HU-Go app - Sickle Cell Disease, Sickle B+ Thalassemia | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 68 | 2021-03-02 | 2026-07-31 |
| Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders Sickle Cell Disease | Recruiting | St. Jude Children's Research Hospital | 352 | 2020-12-17 | 2026-05-01 | |
| An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease MED-Go App - Sickle Cell Disease, Sickle Beta Zero Thalassemia | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 36 | 2020-09-28 | 2026-07-31 |
| ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19 Non applicable, is a patient registry - Hemoglobinopathies, Sickle Cell Disease | Completed | Hospital Universitari Vall d'Hebron Research Institute | 684 | 2020-04-15 | 2025-02-18 | |
| Role of Ajwa Derived Polyphenols in Dyslipidaemias Ajwa Date (phoenix dactylifera) - Dyslipidemias, Hyperglycemia | Not applicable | Unknown | Aga Khan University | 60 | 2019-03-20 | 2019-11-12 |
| A Sickle CEll Disease ComplicatioN Trial SC411, Placebo - Sickle Cell Disease | Phase 3 | Unknown | Micelle BioPharma Inc | 210 | 2019-03-01 | 2019-02-01 |
| Pharmacokinetics of Oral Hydroxyurea Solution Oral Hydroxyurea (100 mg/mL) Solution - Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Nova Laboratories Limited | 33 | 2019-01-03 | 2024-10-28 |
| Ketamine Sickle Cell Disease Ketamine - SC Disease, Pain, Chronic | Phase 3 | Withdrawn | University of South Florida | 2018-09-01 | 2018-09-26 | |
| Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App HU-Go app - Sickle Cell Disease, Sickle B+ Thalassemia | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 33 | 2018-05-15 | 2021-07-29 |
| Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2017-12-19 | 2024-10-09 |
| Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study PROs assessment using sickle cell disease mobile app (SCD-app) - Sickle Cell Disease, Sickle Cell Hemoglobin C | Not applicable | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 40 | 2017-04-04 | 2020-12-21 |
| Effect of Walking on Sand With Dietary Intervention in Overweight Type 2 Diabetes Mellitus Patients. Walking on soft-sand, Walking on Levelled Surface - Walking, Difficulty, Diabetes Mellitus, Type 2 | Not applicable | Completed | Majmaah University | 66 | 2017-01-25 | 2020-09-16 |
| A Study of IMR-687 in Healthy Adult Volunteers IMR-687, Placebo Oral Capsule - Sickle Cell Disease, Sickle-Cell; Hb-SC | Phase 1 | Completed | Cardurion Pharmaceuticals, Inc. | 66 | 2016-10-18 | 2025-05-15 |
| Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE) Hydroxyurea - Hemoglobin SC Disease | Phase 2 | Terminated | Baylor College of Medicine | 1 | 2015-10-12 | 2020-01-27 |
| Decision Aid for Therapeutic Options In Sickle Cell Disease Decision Aid Tool, Standard Practice - Sickle Cell Disease, Sickle Cell Anemia | Not applicable | Completed | Emory University | 134 | 2015-01-01 | 2018-10-09 |
| Treatment of Hemoglobin SC Disease With Hydroxyurea hydroxyurea - Hemoglobin SC Disease | Phase 2 | Terminated | Baylor College of Medicine | 32 | 2014-12-01 | 2020-09-09 |
| Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients Training Program - Sickle Cell Hemoglobin C Disease, Hemoglobin S Disease | Not applicable | Completed | Centre Hospitalier Universitaire de Saint Etienne | 40 | 2014-09-01 | 2021-09-13 |
Showing 20 of 32. Sign in to see all of them.
Anemia, Sickle Cell (26) · Vaso-Occlusive Crises (7) · Hemoglobinopathies (5) · Anemia (4) · Thalassemia (4) · beta-Thalassemia (3) · Acute Chest Syndrome (1) · Acute Pain (1) · Beta Thalassemia, Dominant Inclusion Body Type (1) · COVID-19 (1) · Chronic Pain (1) · Delta-Beta Thalassemia (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1)
Anemia, Hemolytic (32) · Anemia, Hemolytic, Congenital (32) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (32) · Genetic Diseases, Inborn (32) · Hematologic Diseases (32) · Hemic and Lymphatic Diseases (32) · Anemia (28) · Hemoglobinopathies (27) · Anemia, Sickle Cell (6) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Glucose Metabolism Disorders (2) · Lung Diseases (2) · Metabolic Diseases (2) · Neurologic Manifestations (2)
Hydroxyurea (4) · Busulfan (3) · fludarabine (3) · Alemtuzumab (2) · Cyclophosphamide (2) · PEGylated carboxyhemoglobin bovine (2) · Pyrrolidonecarboxylic Acid (2) · Saline Solution (2) · Sodium Chloride (2) · crizanlizumab (2) · fludarabine phosphate (2) · Bortezomib (1) · Buprenorphine (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1)
Ann & Robert H Lurie Children's Hospital of Chicago (4) · Baylor College of Medicine (3) · Novartis Pharmaceuticals (2) · Sangart (2) · St. Jude Children's Research Hospital (2) · Aga Khan University (1) · Cardurion Pharmaceuticals, Inc. (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · GAAD Medical Research Institute Inc. (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Majmaah University (1) · Micelle BioPharma Inc (1) · Natasha Archer (1)
United States (21) · France (3) · United Kingdom (3) · Jamaica (2) · Lebanon (2) · Bahrain (1) · Belgium (1) · Brazil (1) · Canada (1) · India (1) · Netherlands (1) · Pakistan (1) · Qatar (1) · Saudi Arabia (1) · Spain (1)
Sherif M. Badawy, MD, MS (3) · Catherine J. Wu, MD (2) · Tania Small, MD (2) · Vivien Sheehan, MD (2) · Angela E Rankine- Mullings, MD (1) · Beng Fuh, MD (1) · Brigitta Mueller, MD (1) · Carton Dampier, MD (1) · Daniel Armstrong, PhD (1) · Diana J. Wilkie, PhD (1) · Enrico Camporesi, MD (1) · Joanne Filicko-O'Hara, MD (1) · Ken Nedd, M.D. (1) · Kwasi Donyina, Ph.D. (1) · Lakshmanan Krishnamurti, MD (1)
PMID 14550808, PMID 18550258, PMID 20158132, PMID 21275961, PMID 30389037, PMID 31742587, PMID 31799940, PMID 32681734, PMID 36355805, PMID 36529836, PMID 39428602, PMID 39497751
K23HL150232 (2), 1RC2HL101496 (1), 2017 (1), R01HL078536 (1), U01HL133996 (1), U54HL070587 (1), U54HL090569 (1)